Posted by Michael Wonder on 23 Mar 2022
Orphazyme announces withdrawal of European marketing authorisation application for arimoclomol for the treatment of Niemann-Pick disease type C
22 March 2022 - Decision to withdraw the European marketing authorisation application comes ahead of scheduled final vote on the application later this month.
Orphazyme announces that, following the receipt of the negative trend vote by the CHMP as announced on 23 February 2022, the Company has decided to withdraw its European marketing authorisation application for arimoclomol for the treatment of Niemann-Pick disease Type C ahead of a final vote and opinion by the CHMP on the marketing authorisation application scheduled for later this month.
